Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Katayoun I. Amiri"'
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100275- (2022)
Introduction: Programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are standard-of-care treatment for metastatic NSCLC (mNSCLC). Intolerance to treatment/disease progression warrants additional lines of therapy. Real-wo
Externí odkaz:
https://doaj.org/article/d26fdf1d0a124131a149d8f9d7a8fe9a
Autor:
Yan Liu, Oriana E. Hawkins, Yingjun Su, Anna E. Vilgelm, Tammy Sobolik, Yee‐Mon Thu, Sara Kantrow, Ryan C. Splittgerber, Sarah Short, Katayoun I. Amiri, Jeffery A. Ecsedy, Jeffery A. Sosman, Mark C. Kelley, Ann Richmond
Publikováno v:
EMBO Molecular Medicine, Vol 5, Iss 1, Pp 149-166 (2012)
Abstract Oncogene‐induced senescence can provide a protective mechanism against tumour progression. However, production of cytokines and growth factors by senescent cells may contribute to tumour development. Thus, it is unclear whether induction o
Externí odkaz:
https://doaj.org/article/3ceb4ec9997e4c1aa310a31385394045
Autor:
Jeffrey A. Sosman, Ann Richmond, Igor Puzanov, Mark C. Kelley, Elizabeth Koehler, Gregory D. Ayers, Yingchun Yu, Linda W. Horton, Katayoun I. Amiri, Yingjun Su
Purpose: Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-κB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets. We initiated a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be65316355f21c68c92b3eeba631acc
https://doi.org/10.1158/1078-0432.c.6518211.v1
https://doi.org/10.1158/1078-0432.c.6518211.v1
Autor:
Jeffrey A. Sosman, Ann Richmond, Igor Puzanov, Mark C. Kelley, Elizabeth Koehler, Gregory D. Ayers, Yingchun Yu, Linda W. Horton, Katayoun I. Amiri, Yingjun Su
Supplementary Data from A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476ca7b910e275911f84366f6e97f8cb
https://doi.org/10.1158/1078-0432.22441023.v1
https://doi.org/10.1158/1078-0432.22441023.v1
Autor:
Ann Richmond, Jeffrey A. Sosman, Shawn Levy, Darrin D. Stuart, Yu Shyr, Pengcheng Lu, Aixiang Jiang, Katayoun I. Amiri, Kimberly Brown Dahlman, Snjezana Zaja-Milatovic, Tammy Sobolik, Sarah P. Short, Ryan C. Splittgerber, Sara Kantrow, Kelli L. Boyd, Yan Liu, Oriana E. Hawkins, Mark C. Kelley, Anna E. Vilgelm, Yingjun Su
PDF file - 1.2MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1193ac0b5b24895ca3843e6d5be48b75
https://doi.org/10.1158/1078-0432.22443869
https://doi.org/10.1158/1078-0432.22443869
Autor:
Ann Richmond, Jeffrey A. Sosman, Shawn Levy, Darrin D. Stuart, Yu Shyr, Pengcheng Lu, Aixiang Jiang, Katayoun I. Amiri, Kimberly Brown Dahlman, Snjezana Zaja-Milatovic, Tammy Sobolik, Sarah P. Short, Ryan C. Splittgerber, Sara Kantrow, Kelli L. Boyd, Yan Liu, Oriana E. Hawkins, Mark C. Kelley, Anna E. Vilgelm, Yingjun Su
Purpose: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with drug response.Experimental Design: Advanced me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::684a8f0d200c3ae27c63ddee35735568
https://doi.org/10.1158/1078-0432.c.6519989
https://doi.org/10.1158/1078-0432.c.6519989
Autor:
Marc R. Matrana, Ajeet Gajra, Deborah Mulford, Alexandra Sanford, Haythem Ali, David R. Spigel, Liza C. Villaruz, Katayoun I. Amiri, Teng Jin Ong, Nagla Abdel Karim, Edgardo S. Santos, Tymara Berry
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Frontiers in Oncology
Frontiers in Oncology
Introduction The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (EC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::337dbf60e1e6d0b3af61ad44c078236c
https://www.frontiersin.org/article/10.3389/fonc.2018.00253/full
https://www.frontiersin.org/article/10.3389/fonc.2018.00253/full
Autor:
Sara M. Kantrow, Oriana E. Hawkins, Jeffery A. Sosman, Anna E. Vilgelm, Mark C. Kelley, Sarah P. Short, Yan Liu, Yingjun Su, Katayoun I. Amiri, Ryan Splittgerber, Yee Mon Thu, Jeffery A. Ecsedy, Tammy Sobolik, Ann Richmond
Publikováno v:
EMBO Molecular Medicine
Oncogene-induced senescence can provide a protective mechanism against tumour progression. However, production of cytokines and growth factors by senescent cells may contribute to tumour development. Thus, it is unclear whether induction of senescenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1b6881ef83a483cbec9779f48128b0
http://europepmc.org/articles/PMC3569660
http://europepmc.org/articles/PMC3569660
Autor:
Karthik C Konduri, Edward J. Kim, Alexandra Sanford, Daniel Haggstrom, Eric C. Anderson, David Smith, Jonathan H. Goldman, M. Modiano, Jared Weiss, M. Socoteanu, Katayoun I. Amiri, Robert M. Jotte, C. Dahkil, Corey J. Langer
Publikováno v:
Annals of Oncology. 28:v488-v489
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6d1e396b1030a44570d45414c43cd2c
https://doi.org/10.1093/annonc/mdx380.068
https://doi.org/10.1093/annonc/mdx380.068
Autor:
Jeffrey A. Sosman, Gregory D. Ayers, Mark C. Kelley, Katayoun I. Amiri, Yingjun Su, Yingchun Yu, Igor Puzanov, Ann Richmond, Elizabeth Koehler, Linda W. Horton
Publikováno v:
Clinical Cancer Research. 16:348-357
Purpose: Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-κB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets. We initiated a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c7e82463863e121b8572bfb61f6b1d
https://doi.org/10.1158/1078-0432.ccr-09-2087
https://doi.org/10.1158/1078-0432.ccr-09-2087